Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01774253 · ClinicalTrials.gov registry record · Phase 2
Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
A Phase 2 study, sponsored by Giselle Sholler.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT01774253: Clinical Trial Phase 2 study, sponsored by Giselle Sholler.
NCT01774253 is a Phase 2 study that was terminated before completion, run by Giselle Sholler. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01774253, a Phase 2 study, was terminated before completion, sponsored by Giselle Sholler.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate an investigational drug (Vismodegib) for Pontine Glioma that is growing or has come back (reoccurred). This study will look at the tumors response to the study drug, Vismodegib, and will also look at the safety and tolerability of Vismodegib. Vismodegib has been tested in multiple adult clinical trials and one pediatric trial. Laboratory testing in pontine gliomas suggests that this drug may be effective in treating this disease.
Primary Outcome
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or the appearance of new lesions.
Interventions
- DRUG Vismodegib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Why NCT01774253 stopped before completion
NCT01774253 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Vismodegib is the first listed.
NCT01774253 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01774253 about?
NCT01774253 is a clinical study titled "Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma". The purpose of this research study is to evaluate an investigational drug (Vismodegib) for Pontine Glioma that is growing or has come back (reoccurred). This study will look at the tumors response to the study drug, Vismodegib, and will also look at the safety and tolerability of Vismodegib. Vismod...
What is the current status of trial NCT01774253?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2013-05. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01774253?
The interventions under investigation include: Vismodegib (DRUG).
Who is sponsoring clinical trial NCT01774253?
This trial is sponsored by Giselle Sholler, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01774253's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia